TME PHARMA NV (ALTME.PA) Stock Price, Forecast & Analysis
EPA:ALTME • NL0015000YE1
ALTME.PA Key Statistics, Chart & Performance
The current stock price of ALTME.PA is 0.0691 EUR. In the past month the price increased by 14.42%. In the past year, price decreased by -0.14%.
ALTME.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ALTME.PA. When comparing the yearly performance of all stocks, ALTME.PA turns out to be only a medium performer in the overall market: it outperformed 49.89% of all stocks.
ALTME.PA Financial Highlights
Over the last trailing twelve months ALTME.PA reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 86.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -199.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALTME.PA Forecast & Estimates
9 analysts have analysed ALTME.PA and the average price target is 0.11 EUR. This implies a price increase of 52.04% is expected in the next year compared to the current price of 0.0691.
For the next year, analysts expect an EPS growth of 89.47% and a revenue growth -100% for ALTME.PA
ALTME.PA Ownership
ALTME.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 27.62 | 44.705B | ||
| 1AE | ARGENX SE | 28.3 | 44.618B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.471B | ||
| ABVX | ABIVAX SA | N/A | 8.888B | ||
| 2X1 | ABIVAX SA | N/A | 8.872B | ||
| GLPG | GALAPAGOS NV | N/A | 1.891B | ||
| GXE | GALAPAGOS NV | N/A | 1.887B | ||
| IVA | INVENTIVA SA | N/A | 1.16B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.055B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALTME.PA
Company Profile
TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 12 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
Company Info
TME PHARMA NV
Max-Dohrn-Str. 8-10
Berlin BERLIN DE
Employees: 12
Phone: 49307262470
TME PHARMA NV / ALTME.PA FAQ
What does TME PHARMA NV do?
TME Pharma NV is a clinical-stage biopharmaceutical company, which focuses on therapeutics targeting the tumor microenvironment or TME. The company is headquartered in Berlin, Berlin and currently employs 12 full-time employees. The company went IPO on 2018-09-10. The firm specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. their clinical programs in glioblastoma and pancreatic cancer have delivered results and further development is planned.
What is the current price of ALTME stock?
The current stock price of ALTME.PA is 0.0691 EUR. The price decreased by -5.47% in the last trading session.
Does ALTME stock pay dividends?
ALTME.PA does not pay a dividend.
What is the ChartMill rating of TME PHARMA NV stock?
ALTME.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What do analysts say about TME PHARMA NV (ALTME.PA) stock?
9 analysts have analysed ALTME.PA and the average price target is 0.11 EUR. This implies a price increase of 52.04% is expected in the next year compared to the current price of 0.0691.
What is the employee count for ALTME stock?
TME PHARMA NV (ALTME.PA) currently has 12 employees.